NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 8 August 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Iftab Akram Present for all items
4. Dr Alex Cale Present for all items
5. Dr Mark Corbett Present for all items
6. Dr Prithwiraj Das Present for all items
7. Chamkhor Dhillon Present for all items
8. Dr David Foreman Present for all items
9. Dr Rob Forsyth Present for all items
10. Dr Pedro Saramago Goncalves Present for items 5 to 5.2.2
11. Dr Nigel Langford Present for all items
12. Iain McGowan Present for all items
13. Stella O’Brien Present for all items
14. Dr Clare Offer Present for all items
15. Dr Kate Ren Present for all items
16. Dr Arpit Srivastava Present for all items
17. Elizabeth Thurgar Present for all items

NICE staff (key players) present

Ross Dent, Associate Director Present for all items

Louise Jafferally, Project Manager Present for all items

Alex Filby, Heath Technology Assessment Adviser Items 1 to 4.2.2

Sally Doss, Heath Technology Assessment Adviser Items 5 to 5.2.2

Tom Jarratt, Heath Technology Assessment Analyst Items 1 to 4.2.2

Anita Sangha, Heath Technology Assessment Analyst Items 5 to 5.2.2

Madiha Adam, Heath Technology Assessment Analyst Items 5 to 5.2.2

External assessment group representatives present

Ana Duarte, York Health Economics Group Items 1 to 4.1.3

Pedro Saramango Goncalves, York Health Economics Group Items 1 to 4.1.3

Angela Stainthrope, Liverpool Reviews and Implementation Group Items 5 to 5.1.3

Marty Chaplin, Liverpool Reviews and Implementation Group Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Present for all items

Dr Wendy Osborne, Consultant Haematologist, clinical expert, nominated by Roche, Items 1 to 4.1.3

Dr William Townsend, Consultant Haematologist, clinical expert, nominated by NCRI-ACP-RCP-RCR, Items 1 to 4.1.3

Dr Mairéad McNamara, Senior Lecturer/Honorary Consultant in Medical Oncology, clinical expert, nominated by AstraZeneca, Items 5 to 5.1.3

Professor John Bridgewater, Professor and Honorary Consultant in Medical Oncology, clinical expert, nominated by NCRI-RCP and Cholangiocarcinoma UK, Items 5 to 5.1.3

Helen Morement, patient expert, The Cholangiocarcinoma Charity, nominated by AMMF, Items 5 to 5.1.3

Andrea Sheardown, patient expert, The Cholangiocarcinoma Charity, nominated by AMMF, Items 5 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Professor Andrew Renehan, Dr Britta Stordel, John Hampson, Michael Chambers, Dr Steve Lloyd, and Ugochi Nwulu.

### News and announcements

* 1. .

### Minutes from the last meeting

* 1. The committee were informed that the minutes of the committee meeting held on Tuesday 11 July 2023 would be circulated post-meeting.

### Appraisal of Appraisal of Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments [ID3970]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Roche.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10862/documents).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Prithwiraj Das, Dr David Foreman and Stella O’Brien.
  2. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10862>.

### Appraisal of Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta10920/documents)
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Iftab Akram, Dr Mark Corbett and Stella O’Brien.
  2. Part 2 - Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10920>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 12 September 2023 and will start promptly at 9am.